Nikolaos from Greece

Registered at the short selling broker Skilling, 2 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Novartis AG (NVS) stock information

Novartis AG

24h Change

-0.09 %


Live rate: Market closed

Stock data per Friday 22 May, 2020

New York Stock Exchange
-0.08 (-0.09%)
US Market is closed

Live Stock price in graph for Novartis AG (NVS)

Data updated continously for NVS, showing up to the 500 most recent 100 data points

  • Latest Volume

    1,356,741 (-20.01 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change



Latest news about Novartis AG

Below you can find the most recent news posts about Novartis AG, primarily from US and UK based news sources.

Novartis plant saved for another year as closure delayed

Thursday, 21 May 2020, 16:55:48
Pharmaceutical giant confirms it is keeping large parts of plant open and retaining staff
— Grimsby Live

Stay of execution for huge Novartis pharmaceutical plant

Thursday, 21 May 2020, 16:26:06
Grimsby site to be retained for a further year after initial 2020 closure pushed back
— Business Live

Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

Tuesday, 19 May 2020, 14:52:00
Novartis’ (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
— Zacks Investment Research

Novartis : Zolgensma Gets Conditional EU Approval | MarketScreener

Tuesday, 19 May 2020, 06:05:03
By Olivia Bugault Novartis AG said Tuesday that its Zolgensma gene therapy for patients with spinal muscular atrophy has been conditionally approved in Europe. The European Commission… | May 19, 2020
— MarketScreener

Regenerative Medicine Industry Outlook to 2025 Featuring Novartis, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Roche and More

Thursday, 14 May 2020, 13:00:00
DUBLIN, May 14, 2020 /PRNewswire/ — The “Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application, By Material, By Cell, By Product, By Technique, By Distribution Channel, By Region, Forecast & Opportunities, 2025″…
— PR Newswire